TREM2 (triggering receptor expressed on myeloid cells 2) is a transmembrane receptor belonging to the immunoglobulin (Ig) family. It is composed of an extracellular region containing the Ig-like domain and a cytoplasmic tail. It has a transmembrane region of 33 amino acids followed by a cytoplasmic tail. It is expressed on myeloid cells such as, macrophages found in tissue and dendritic cells, on microglial cells in the brain.
Immunogen
Peptide with sequence CHGQKPGTHPPSELD, from the C Terminus of the protein sequence according to NP_061838.1.
Application
Anti-TREM2 (C-terminal) antibody produced in goat is suitable for indirect ELISA and immunohistochemistry studies.
Biochem/physiol Actions
TREM2 (triggering receptor expressed on myeloid cells 2) is involved in the bacterial phagocytosis and regulation of inflammatory response. Its presence in microglia helps to remove the neural debris i.e. amyloid β peptide (Aβ) on microglia. TREM2 suppresses the ability of microglia to phagocytize Aβ, and disturbs the pro-inflammatory activity of these cells. Parkinson′s disease (PD) is portrayed by the degeneration of dopaminergic neurons, in the substantia nigra standards compacta district of the cerebrum. TREM2 binds specifically to the ligands expressed by these dopaminergic neurons. Likewise, microgliosis is additionally involved in the movement of PD. Hence, several type of TREM2 gene might be linked to susceptibility to PD. p.R47H polymorphism in this gene is identified with increased risk of sporadic amyotrophic sidelong sclerosis. Mutation in TREM2 is also associated with polycystic lipomembranous osteodysplaysia with sclerosing leukoencephalop.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Neurobiology of aging, 35(10), 2419-2419 (2014-06-10)
TREM2 mutations were first identified in Nasu-Hakola disease, a rare autosomal recessive disease characterized by recurrent fractures because of bone cysts and presenile dementia. Recently, homozygous and compound heterozygous TREM2 mutations were identified in rare families with frontotemporal lobar degeneration
Alzheimer's disease is one of the main causes of dementia among elderly individuals and leads to the neurodegeneration of different areas of the brain, resulting in memory impairments and loss of cognitive functions. Recently, a rare variant that is associated
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which microglia play a significant and active role. Recently, a rare missense variant (p.R47H) in the microglial activating gene TREM2 was found to increase the risk of several neurodegenerative diseases
TREM2 and neurodegenerative disease.
Bruno A Benitez et al.
The New England journal of medicine, 369(16), 1567-1568 (2013-10-18)
European journal of immunology, 33(2), 567-577 (2003-03-21)
We have characterized a cluster of single immunoglobulin variable (IgV) domain receptors centromeric of the major histocompatibility complex (MHC) on human chromosome 6. In addition to triggering receptor expressed on myeloid cells (TREM)-1 and TREM2, the cluster contains NKp44, a
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.